サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1429516

インスリン医薬品の世界市場レポート 2024

Insulin Drugs Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.86円
インスリン医薬品の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

インスリン医薬品の市場規模は、今後数年間で急速に成長すると予想されています。 2028年には10.6%の年間複合成長率（CAGR）で518億1,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、疾病負担の増加、政府の取り組み、協力を伴う研究開発（R&D）活動の増加などの要因に起因すると考えられます。予測期間に予想される重要な動向には、製品提供を強化するための新製品の発売、合併と買収による製品ポートフォリオと事業の拡大、製品提供を促進するための戦略的パートナーシップの採用、製品開発のための研究開発への投資の増加などが含まれます。新しいインスリン投与方法、および研究開発コストを削減し、開発スケジュールを加速するための高度なソリューションへの投資です。

長時間労働、身体活動の減少、不健康な食生活を特徴とするライフスタイルの変化によって糖尿病の有病率が増加しており、予測期間中に糖尿病薬の需要が高まると予想されます。座りっぱなしのライフスタイルは糖尿病の発生率の上昇と関連しており、肥満に苦しむ人は2型糖尿病を発症するリスクが最大80倍増加することに直面しています。世界保健機関（WHO）の予測では、2030年までに英国の男性の74%、女性の64%が過体重になると予想されており、憂慮すべき傾向が示されています。この糖尿病症例の急増により、糖尿病治療市場が促進される可能性があります。

インスリン医薬品市場は、糖尿病の既知の危険因子である肥満の有病率の上昇により、成長する態勢が整っています。健康に悪影響を及ぼす過剰な体脂肪を特徴とする肥満は、糖尿病の発症と密接に関連しています。肥満の文脈で使用されるインスリン医薬品は、体重増加に寄与し、肥満の問題を悪化させる可能性があります。たとえば英国では、政府デジタルサービスの予測によると、2021年から2022年にかけて18歳以上の肥満が25.2%増加することが示されています。肥満率の上昇は、インスリン医薬品市場の成長の主な原動力です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界のインスリン医薬品市場、製品タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 基礎インスリンまたは持効性インスリン
  • ボーラスまたは速効型インスリン
  • プレミックス
  • 中間型および短時間作用型インスリン
  • 世界のインスリン医薬品市場、由来タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • インスリン類似体
  • ヒトインスリン
  • 世界のインスリン医薬品市場、医薬品分類別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • ブランド医薬品
  • ジェネリック医薬品
  • 世界のインスリン医薬品市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 2型糖尿病
  • 1型糖尿病
  • 妊娠糖尿病
  • 世界のインスリン医薬品市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • 小売薬局
  • オンライン

第7章 地域および国の分析

  • 世界のインスリン医薬品市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
  • 世界のインスリン医薬品市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • インスリン医薬品市場の競合情勢
  • インスリン医薬品市場の企業プロファイル
    • Novo Nordisk
    • Sanofi SA
    • Eli Lilly And Company
    • Biocon Ltd
    • and Gan &Lee Pharmaceuticals

第31章 その他の大手および革新的な企業

  • Bioton
  • Wockhardt Ltd
  • Julphar
  • Tonghua Dongbao Pharmaceutical
  • AstraZeneca
  • Mehar healthcare
  • GE Healthcare
  • Philips Healthcare India
  • Shandong WeiGao Group Medical Polymer Company Limited
  • Yuwell Medical Equipment &Supply Co
  • Terumo
  • NIPRO
  • Olympus Medical Systems
  • Hitachi Medico
  • Nihon Kohden

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r14487

Insulin drugs are medications prescribed for the treatment of diabetes, encompassing both type 1 diabetes and type 2 diabetes mellitus. These drugs come in various types, preparations, and dosage amounts. Insulin, a hormone naturally produced in the body, plays a crucial role in facilitating the uptake of glucose (sugar) by cells throughout the body, converting it into a form usable for energy.

The primary product types of insulin drugs include basal or long-acting insulins, bolus or fast-acting insulins, pre-mixed insulins, and intermediate and short-acting insulins. Basal or long-acting insulins are utilized in diabetes management to provide a slow, steady release of insulin throughout the day and night. Insulin source types include insulin analogs and human insulin, while drugs are categorized into branded and generic drugs, distributed through hospital pharmacies, retail pharmacies, and online platforms. The various applications of insulin drugs encompass type II diabetes, type I diabetes, and gestational diabetes.

The insulin drugs market research report is one of a series of new reports from The Business Research Company that provides insulin drugs market statistics, including insulin drugs industry global market size, regional shares, competitors with an insulin drugs market share, detailed insulin drugs market segments, market trends and opportunities, and any further data you may need to thrive in the insulin drugs industry. This insulin drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The insulin drugs market size has grown rapidly in recent years. It will grow from $31.09 billion in 2023 to $34.6 billion in 2024 at a compound annual growth rate (CAGR) of 11.3%. The expansion observed in the historical period can be attributed to factors such as the increase in diabetes prevalence, growth in emerging markets, an increased geriatric population, and the growth in the use of insulin analogues.

The insulin drugs market size is expected to see rapid growth in the next few years. It will grow to $51.81 billion in 2028 at a compound annual growth rate (CAGR) of 10.6%. The anticipated growth in the forecast period can be attributed to factors such as the increase in disease burden, government initiatives, and a rise in research and development (R&D) activities along with collaborations. Significant trends expected in the forecast period include the launch of new products to enhance product offerings, the expansion of product portfolios and businesses through mergers and acquisitions, the adoption of strategic partnerships to promote product offerings, increased investments in research and development for the development of new insulin delivery methods, and the investment in advanced solutions to reduce R&D costs and accelerate development timelines.

The increasing prevalence of diabetes, driven by changing lifestyles marked by long working hours, reduced physical activity, and unhealthy eating habits, is anticipated to boost the demand for diabetes drugs in the forecast period. Sedentary lifestyles have been linked to a higher incidence of diabetes, and individuals suffering from obesity face up to an 80-fold increased risk of developing type 2 diabetes. Projections from the World Health Organization (WHO) indicate a concerning trend, with an expected 74% of men and 64% of women in the UK being overweight by 2030. This surge in diabetes cases is likely to propel the diabetes therapies market.

The insulin drugs market is poised for growth due to the rising prevalence of obesity, a known risk factor for diabetes. Obesity, characterized by excess body fat adversely affecting health, is closely linked to diabetes development. Insulin drugs, used in the context of obesity, can contribute to weight gain, exacerbating the obesity issue. In England, for instance, projections from the Government Digital Service indicate a 25.2% increase in obesity among individuals aged 18 and older in the period 2021-2022. The escalating rates of obesity are a key driver for the growth of the insulin drugs market.

A discernible trend in the insulin market is the increasing number of mergers and acquisitions focused on developing new formulations. Companies are actively investing in innovative medicines for diabetes treatment. Researchers at Lund University Diabetes Centre utilized CRISPR, a genome modification tool, to turn off genes responsible for diabetes, resulting in increased insulin production and decreased beta cell death. Novo Nordisk has developed a diabetes pill based on glucagon-such as peptide-1 (GLP-1s) that stimulates insulin production, anticipating significant annual sales.

Major companies in the insulin drugs market are emphasizing product innovation, exemplified by the introduction of the triple fixed-dose combination (FDC) of teneligliptin with pioglitazone and metformin. Glenmark Pharmaceuticals Limited, an Indian pharmaceutical company, launched Zita-PioMet, a triple FDC for treating type 2 diabetes and high insulin resistance. This innovation aims to improve glycemic control in adults with uncontrolled diabetes despite other treatments.

In July 2021, Eli Lilly and Company, a US-based pharmaceutical company, acquired Protomer Technologies Inc. for $1 billion. This acquisition enhances Lilly's capabilities in insulin therapy advancements, particularly in developing glucose-sensing insulin. Protomer Technologies, a pre-clinical stage biotechnology company, specializes in research and technology development for metabolic disorders, aligning with Lilly's commitment to improving the lives of diabetes patients.

Major companies operating in the insulin drugs market report are Novo Nordisk, Sanofi S.A., Eli Lilly And Company, Biocon Ltd., and Gan & Lee Pharmaceuticals, Bioton, Wockhardt Ltd., Julphar, Tonghua Dongbao Pharmaceutical, AstraZeneca, Mehar healthcare, GE Healthcare, Philips Healthcare India, Shandong WeiGao Group Medical Polymer Company Limited, Yuwell Medical Equipment & Supply Co, Terumo, NIPRO, Olympus Medical Systems, Hitachi Medico, Nihon Kohden, Fukuda Denshi, Emperra GmbH E-Health Technologies, DIABNEXT™, Berlin-Chemie AG, Ypsomed Holding AG, Patients Pending Ltd., Dexcom, Johnson and Johnson, Medtronic, Abbott Laboratories, Acon Laboratories, Ypsomed AG, Tandem Diabetes Care, Inc., Becton, Dickinson, Insulet Corporation, AJA Pharma, SEDICO Pharmaceutical Company, Pfizer

North America was the largest region in the insulin drugs market in 2023. The Middle East is expected to be the largest growing region in the global insulin drugs market share during the forecast period. The regions covered in the insulin drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the insulin drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The insulin drugs market consists of sales of rapid-acting insulin, short-acting insulin, and mixed insulin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Insulin Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on insulin drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for insulin drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The insulin drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Product Type: Basal Or Long-Acting Insulins; Bolus Or Fast-Acting Insulins; Pre-Mixed; And Intermediate And Short Acting Insulins
  • 2) By Source Type: Insulin Analogs; And Human Insulin
  • 4) By Drug Classification: Branded Drugs, And Generic Drugs
  • 3) By Application: Type 2 Diabetes; Type 1 Diabetes; And Gestational Diabetes
  • 5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; And Online
  • Companies Mentioned: Novo Nordisk; Sanofi S.A.; Eli Lilly And Company; Biocon Ltd; and Gan & Lee Pharmaceuticals
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Insulin Drugs Market Characteristics

3. Insulin Drugs Market Trends And Strategies

4. Insulin Drugs Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Insulin Drugs Market Size and Growth

  • 5.1. Global Insulin Drugs Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Insulin Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Insulin Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Insulin Drugs Market Segmentation

  • 6.1. Global Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Basal Or Long-Acting Insulins
  • Bolus Or Fast-Acting Insulins
  • Pre-Mixed
  • Intermediate And Short Acting Insulins
  • 6.2. Global Insulin Drugs Market, Segmentation By Source Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Insulin Analogs
  • Human Insulin
  • 6.3. Global Insulin Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Branded Drugs
  • Generic Drugs
  • 6.4. Global Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Type 2 Diabetes
  • Type 1 Diabetes
  • Gestational Diabetes
  • 6.5. Global Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online

7. Insulin Drugs Market Regional And Country Analysis

  • 7.1. Global Insulin Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Insulin Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Insulin Drugs Market

  • 8.1. Asia-Pacific Insulin Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Insulin Drugs Market

  • 9.1. China Insulin Drugs Market Overview
  • 9.2. China Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Insulin Drugs Market

  • 10.1. India Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Insulin Drugs Market

  • 11.1. Japan Insulin Drugs Market Overview
  • 11.2. Japan Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Insulin Drugs Market

  • 12.1. Australia Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Insulin Drugs Market

  • 13.1. Indonesia Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Insulin Drugs Market

  • 14.1. South Korea Insulin Drugs Market Overview
  • 14.2. South Korea Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Insulin Drugs Market

  • 15.1. Western Europe Insulin Drugs Market Overview
  • 15.2. Western Europe Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Insulin Drugs Market

  • 16.1. UK Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Insulin Drugs Market

  • 17.1. Germany Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Insulin Drugs Market

  • 18.1. France Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Insulin Drugs Market

  • 19.1. Italy Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Insulin Drugs Market

  • 20.1. Spain Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Insulin Drugs Market

  • 21.1. Eastern Europe Insulin Drugs Market Overview
  • 21.2. Eastern Europe Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Insulin Drugs Market

  • 22.1. Russia Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Insulin Drugs Market

  • 23.1. North America Insulin Drugs Market Overview
  • 23.2. North America Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Insulin Drugs Market

  • 24.1. USA Insulin Drugs Market Overview
  • 24.2. USA Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Insulin Drugs Market

  • 25.1. Canada Insulin Drugs Market Overview
  • 25.2. Canada Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Insulin Drugs Market

  • 26.1. South America Insulin Drugs Market Overview
  • 26.2. South America Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Insulin Drugs Market

  • 27.1. Brazil Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Insulin Drugs Market

  • 28.1. Middle East Insulin Drugs Market Overview
  • 28.2. Middle East Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Insulin Drugs Market

  • 29.1. Africa Insulin Drugs Market Overview
  • 29.2. Africa Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Insulin Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Insulin Drugs Market Competitive Landscape And Company Profiles

  • 30.1. Insulin Drugs Market Competitive Landscape
  • 30.2. Insulin Drugs Market Company Profiles
    • 30.2.1. Novo Nordisk
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Sanofi S.A.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Eli Lilly And Company
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Biocon Ltd
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. and Gan & Lee Pharmaceuticals
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Insulin Drugs Market Other Major And Innovative Companies

  • 31.1. Bioton
  • 31.2. Wockhardt Ltd
  • 31.3. Julphar
  • 31.4. Tonghua Dongbao Pharmaceutical
  • 31.5. AstraZeneca
  • 31.6. Mehar healthcare
  • 31.7. GE Healthcare
  • 31.8. Philips Healthcare India
  • 31.9. Shandong WeiGao Group Medical Polymer Company Limited
  • 31.10. Yuwell Medical Equipment & Supply Co
  • 31.11. Terumo
  • 31.12. NIPRO
  • 31.13. Olympus Medical Systems
  • 31.14. Hitachi Medico
  • 31.15. Nihon Kohden

32. Global Insulin Drugs Market Competitive Benchmarking

33. Global Insulin Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Insulin Drugs Market

35. Insulin Drugs Market Future Outlook and Potential Analysis

  • 35.1 Insulin Drugs Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Insulin Drugs Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Insulin Drugs Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer